德琪醫藥(06996.HK)附屬獲中國政府獎勵2,678萬人幣
德琪醫藥(06996.HK)公布,於今年11月27日,公司於中國的一家附屬公司兼主要運營實體德琪浙江從中國浙江省紹興濱海新區管理委員會收到一筆政府獎勵2,678.1萬元人民幣,以認可公司對濱海新區生物製藥創新的貢獻。該獎勵資金已全數劃撥至公司資本賬。
根據相關會計準則,公司將於截至2020年12月31日止年度將該獎勵確認為「其他收入」,將對公司截至2020年12月31日止年度的年度業績產生一定正面影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.